Name
*
First Name
Last Name
Email
*
example@example.com
What best describes your title?
*
MD
RN/NP
PA
Professor
Industry
Other
How many patients do you currently see each month with myasthenia gravis?
Less than 5
5-15
16-25
26 or more
N/A
How many years have you been in practice?
1. A 47-year-old woman with AChR-Ab+ gMG has been on prednisone 20 mg/day for 3 years plus monthly IVIg. Her MG-ADL is 4, and she has gained weight and has insomnia. She is asking about B-cell–directed options. Which statement is best supported by randomized trial evidence?
*
Rituximab met its steroid-sparing primary endpoint in the phase 2 BeatMG Trial in AChR-Ab+ gMG
The BAFF-only inhibitor belimumab significantly improved QMG vs placebo at 24 weeks
Inebilizumab significantly improved MG-ADL vs placebo at week 26 in a combined AChR-Ab+/MuSK-Ab+ population
Her MG-ADL of 4 means she has reached the minimal symptom expression (MSE) target, so no change is needed
2. Which statement best describes telitacicept?
*
A TACI-Fc fusion protein that neutralizes both BAFF and APRIL. In a phase 3 trial in China, it produced a greater mean MG-ADL improvement than placebo at week 24 (−6.4 vs −1.6).
An anti-CD19 monoclonal antibody that depletes B cells through ADCC. In phase 3, it was given IV every 6 months after loading doses.
An FcRn blocker that speeds up IgG breakdown. In phase 3, it cut IgG by more than 70% within the first week.
A selective BAFF-only inhibitor. BAFF blockade alone met its primary endpoint in a randomized phase 2 gMG trial.
3. A 38-year-old woman with MuSK-Ab+ gMG responded to rituximab in the past. She now has recurring dysphagia and dysarthria, with an MG-ADL of 7. Which plan is most appropriate?
*
Start a complement C5 inhibitor for fast control of bulbar symptoms
Use a fast IgG-lowering approach (e.g., an FcRn inhibitor) plus B-cell/plasma-cell–directed therapy for lasting control, and consider BAFF/APRIL inhibition through a clinical trial
Raise pyridostigmine to the maximum tolerated dose as her only therapy
Continue her current management and reassess in 6 months, given her past rituximab response
Please rate the extent to which this activity met the following objectives:
Rows
Poor
Fair
Good
Very Good
Excellent
Review the current therapeutic landscape for the disease-modifying treatment of patients with gMG and identify unmet patient needs
Discuss the mode of action and current clinical trial data for dual fusion protein treatments for patients with gMG
Develop strategies for developing individualized treatment plans to manage patients with AChR-Ab or MuSK-Ab positive gMG, including the potential role of BAFF/APRIL inhibitors
Please provide feedback regarding your experience with this activity:
Rows
Poor
Fair
Good
Very Good
Excellent
Overall
Content
Usefulness
Do you feel this activity was fair, balanced, and free of commercial bias?
Yes
No
If no, please explain:
This educational activity will result in a change in my role as a healthcare team member.
Yes
No
N/A
Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
I gained new strategies/skills/information that my team can apply to practice
I plan to implement new strategies/skills/information in my practice
I will be more competent in my team’s management of patient care
I will improve my communication with the healthcare team
What factors beyond clinical care that affect the health of your patients does your team experience?
Date
-
Month
-
Day
Year
2 digit month, 2 digit day, 4 digit year
Date
Course Title
Credits
Submit
Should be Empty: